Closing Out 2025 With Purpose: Celebrating Pharmacy’s Progress and Promise

In this final 2025 issue of Pharmacy Practice in Focus: Health Systems, thought leaders explore the expanding impact of pharmacy professionals as leaders, innovators, and advocates across diverse areas of care—from heart failure (HF) prevention to leadership strategy and novel therapeutics. Together, these pieces showcase how pharmacy continues to lead progress in patient-centered care, scientific advancement, and health system transformation.

With comments from Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, BCPS-AQ Cardiology, CACP, an adjunct associate professor with the University of Kentucky College of Pharmacy in Lexington, this issue’s cover feature discusses shifts from reactive treatment to proactive treatment in the HF space. A new joint statement, coauthored by Beavers, reframes HF as a preventable condition and urges earlier intervention and integrated care across patients’ life spans. Pharmacists are at the forefront of this approach by leading prevention clinics, optimizing therapy, monitoring comorbidities, and ensuring medication adherence from primary prevention through advanced HF management.

Modern pharmacy leadership has evolved beyond managing medications and operations to shaping vision, culture, and strategy that center on patient care, writes Madeline Camejo, PharmD, MS, CPEL, in a Practice Insights article. Today’s chief pharmacy officers must balance clinical excellence, financial stewardship, and team empowerment amid workforce shortages, policy shifts, and rapid technological change. Effective leaders transform challenges into opportunities by uniting the profession with a shared voice, leveraging data to demonstrate impact, and leading innovation responsibly, particularly as technology and precision medicine reshape health care. Key to this leadership is investing in people through mentorship, recognition, and inclusion, ensuring every team member feels valued and empowered to contribute.

In a Therapy Spotlight article, authors Tracy Mahvan, PharmD, RPh, BCGP; Sebastian Mooney, PharmD candidate 2026; and McKayla Adkison, PharmD candidate 2026, discuss the FDA’s recent approval of Tonmya, a sublingual formulation of cyclobenzaprine hydrochloride, as a new treatment for fibromyalgia.

This formulation offers rapid absorption, improved bioavailability, and fewer systemic adverse effects compared with prior formulations. The approval of sublingual cyclobenzaprine hydrochloride represents an important advancement, expanding treatment options for patients while offering a novel, effective approach to managing fibromyalgia symptoms.

As the year comes to a close, it is important to reflect on the momentum and vision that drive the pharmacy profession forward. These insights offer a unifying theme: pharmacy’s continuously growing influence as both a clinical and strategic cornerstone within health care. In 2026, let us continue to recognize collaboration, innovation, and leadership as the pharmacist’s enduring commitment to improving outcomes and transforming care for all patients.